The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Kranjec C, Eilertsen IA, Nunes L, Moosavi SH, Berg KCG, Eknæs M, Hektoen M, Niederdorfer B, Lind GE, Skotheim RI, Sveen A, Lothe RA(2026) Common gene mutations in 103 authenticated colorectal cancer cell lines Oncogenesis(in press) DOI 10.1038/s41389-026-00599-0, PubMed 41593049
Svalheim KG, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, Kyte JA(2026) Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer Breast, 86, 104704(in press) DOI 10.1016/j.breast.2026.104704, PubMed 41581361
Landsverk HB, Sandquist LE, Bay LTE, Hauge S, van Bijsterveldt L, Lindbergsengen L, Lund-Andersen C, Kanduri C, Lyng H, Fjeldbo CS, Hompland T, Humphrey TC, Syljuåsen RG(2026) Transcription termination counteracts DNA damage after WEE1 inhibition Nucleic Acids Res, 54(3) DOI 10.1093/nar/gkaf1487, PubMed 41569153
Thorgersen EB, Dagenborg VJ, Schultz JK(2026) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: How, to whom, and is centralization needed? Scand J Surg, 14574969261418796(in press) DOI 10.1177/14574969261418796, PubMed 41655138
Morken S, Langer SW, Hjortland GO, Sundlöv A, Hofsli E, Ladekarl M, Tabaksblat E, Vestermark LW, Svensson J, Knigge U, Nunes L, Glimelius B, Pfeiffer P, Aasebø K, Assmus J, Vassella E, Lothe IMB, Couvelard A, Perren A, Knappskog S, Sorbye H(2026) Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas Int J Cancer(in press) DOI 10.1002/ijc.70367, PubMed 41642024
Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido Lopez P, Gregorc V, Haakensen VD, Hiltermann TJN, Kao S, McDonald F, Mornex F, Moskovitz M, Peters S, Siva S, Solomon B, Qiao Y, Anand S, Chander P, Shcherbakova T, Diaz Perez I, Filippi AR(2026) Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC ESMO Open, 11(2), 106070(in press) DOI 10.1016/j.esmoop.2026.106070, PubMed 41643268